THERAVET SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.582 EUR | 0.00% |
|
+0.34% | -59.86% |
| May. 21 | TheraVet SA Announces Early Completion of Patient Recruitment of the Visco-VET Clinical Study | CI |
| May. 07 | FOMO is Back |  |
| Sales 2021 | 1.94M 2.09M | Sales 2022 | 1.6M 1.73M | Capitalization | 8.06M 8.68M |
|---|---|---|---|---|---|
| Net income 2021 | -1M -1.08M | Net income 2022 | -2M -2.15M | EV / Sales 2021 | 7.08 x |
| Net cash position 2021 | 4.63M 4.99M | Net cash position 2022 | 2.14M 2.3M | EV / Sales 2022 | 3.7 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-3.48
x | Employees | 8 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | +0.34% | ||
| Current month | -2.68% | ||
| 1 month | -17.56% | ||
| 3 months | -41.21% | ||
| 6 months | -61.20% | ||
| Current year | -59.86% |
1 week
0.53
0.58
1 month
0.530.71
Current year
0.531.46
1 year
0.532.40
3 years
0.538.56
5 years
0.538.56
10 years
0.538.56
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | - | 17-11-20 | |
Rodolphe Lebrun
DFI | Director of Finance/CFO | - | 23-10-23 |
Celine Molle
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 17-11-20 | |
Simon Wheeler
CHM | Chairman | - | 21-12-19 |
Nesya Goris
BRD | Director/Board Member | - | 21-12-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 0.582 | 0.00% | 22 |
| 24-06-07 | 0.582 | +0.34% | 7,494 |
| 24-06-06 | 0.58 | 0.00% | 8,335 |
| 24-06-05 | 0.58 | 0.00% | 3,920 |
| 24-06-04 | 0.58 | 0.00% | 5,377 |
Real-time Euronext Paris, June 10, 2024 at 03:47 am EDT
More quotes
TheraVet SA is specialized in the development of pharmaceutical products for the treatment of osteoarticular diseases in pets.
At the end of 2023, the company had a portfolio of 2 products in the clinical development phase: Visco-Vet for the treatment of limping associated with osteoarthritis in dogs and Biocera-Vet for osseointegration and bone remodeling.
Calendar
2024-09-12
- Q2 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -59.86% | 2.02M | |
| +18.77% | 125B | |
| +14.05% | 108B | |
| -7.16% | 23.64B | |
| +2.07% | 22.39B | |
| -10.79% | 17.78B | |
| -41.74% | 16.43B | |
| -13.47% | 16.34B | |
| +2.23% | 13.56B | |
| +27.13% | 11.59B |
- Stock Market
- Equities
- ALVET Stock
